34 results about "Fetuin" patented technology

Compositions and methods for isolating and expanding human mesenchymal stem / progenitor cells through multiple passages in defined serum-free environments are provided. The culture media compositions includes a basal medium supplemented with a nutrient mixture such as Ham's F12 nutrient mixture, glutamine, buffer solutions such as sodium bicarbonate and hepes, serum albumin, a lipid mixture, insulin, transferrin, putrescine, progesterone, fetuin, hydrocortisone, ascorbic acid or its analogues such as ascorbic acid-2-phosphate, fibroblast growth factor and transforming growth factor β, and are free of serum or other undefined serum substitutes such as platelet lysate. Methods employing these compositions and protein-coated surfaces for the isolation of mesenchymal stem / progenitor cells from human bone marrow and other tissues such as adipose tissue are also provided. Finally, methods are also provided for serially expanding these cells through multiple passages without losing mesenchymal stem cell-specific proliferative, phenotypical and differentiation characteristics.

The invention provides a serum-free adipose-derived stem cell culture medium, belonging to the technical field of stem cells. The serum-free adipose-derived stem cell culture medium comprises an IMDM (Iscove's modified Dulbecco's medium) basal culture medium, recombinant human insulin, recombinant transferrin, vitamin C, human serum albumin, fibroblast growth factor, platelet-derived growth factor, epidermal growth factor, insuline-like growth factor, transforming growth factor, fiber connexin, fetuin, tea polyphenol and stem cell growth factor. The serum-free adipose-derived stem cell culture medium provided by the invention does not need to perform culture bottle coating, and has the advantages of cell adherent property, favorable morphology and high cell proliferation rate.

Disclosed is a method of transdifferentiating an epidermal basal cell into a cell having one or more morphological, physiological and / or immunological features of a neural progenitor, neuronal, or glial cell by culturing a proliferating epidermal basal cell population derived from the skin of a mammalian subject; exposing the epidermal basal cell(s) to an antagonist of bone morphogenetic protein (BMP), such as fetuin, noggin, chordin, gremlin, or follistatin; and growing the cell(s) in the presence of at least one antisense oligonucleotide comprising a segment of a human MSX1 gene and / or a segment of a human HES1 gene, or homologous non-human counterpart of either of these. Also disclosed is a transdifferentiated cell of epidermal origin and cell cultures derived therefrom. In addition, methods of using the inventive transdifferentiated cell(s) and cell cultures to identify a novel nerve growth factor or to screen a potential chemotherapeutic agent by detecting the presence or absence of an effect, in vitro, on a morphological, physiological and / or molecular biological property of the transdifferentiated cell(s) are described, as is a method of using the transdifferentiated cell(s) and cell cultures to screen a potential chemotherapeutic agent to treat a nervous system disorder of genetic origin. A kit useful for practicing the methods is disclosed

The invention provides a serum-free mesenchymal stem cell nutrient solution, which is simple in formula, low in cost and high in safety. The serum-free mesenchymal stem cell nutrient solution comprises a serum-free animal cell culture medium, a B27 serum-free additive, bFGFs (basic fibroblast growth factors) and EGFs (epidermal growth factors), wherein the nutrient solution also comprises fetuin and antibiotics. The nutrient solution does not contain animal serum, has higher safety and definite formula components, and is suitable for clinical treatment. Meanwhile, according to the serum-free mesenchymal stem cell nutrient solution, human fat stem cells can be normally attached to the surface of a culture vessel and grow, the antibiotics are added into the formula components, and the formula is simpler compared with that of the general serum-free nutrient solution. For the fat stem cells cultured according to the conventional formula, the cells began to differentiate and slowly grow after two generations. Compared with the fat stem cells cultured according to the conventional formula, the fat stem cells cultured according to the formula of the serum-free mesenchymal stem cell nutrient solution do not have the phenomena of differentiation and slow growth after being tested, so that the serum-free mesenchymal stem cell nutrient solution is extremely suitable for the growth of the fat stem cells and gum stem cells.

The invention provides a serum-free human amniotic mesenchymal stem cell culture medium, and belongs to the technical field of stem cells. The serum-free human amniotic mesenchymal stem cell culture medium comprises the following components: an IMDM basal culture medium, recombinant human insulin, recombinant transferrin, vitamin C, human serum albumin, fibroblast growth factors, platelet-derived growth factors, epidermal growth factors, insulin-like growth factors, transforming growth factors, fibronectin, fetuin, putrescine salt and recombinant human activin. The serum-free human amniotic mesenchymal stem cell culture medium provided by the invention does not need a culture bottle coating process, and is good in cell adherence and morphology and high in cell proliferation rate.

The invention provides an induced pluripotent stem cell culture medium for the field of biotechnology as well as application and a cultivation method thereof. IMDM / F12 is used as a basal culture medium. Each 500mL of IMDM / F12 basal culture medium comprises recombinant human insulin, recombination transferrin, vitamin C, human albumin, bFGF, PDGF-bb, EGF, IGF-1, TGF-beta, fibronectin, Fetuin, Betacellulin, beta-mercaptoethanol and Thiazovivin. As animal serum is completely unavailable in the induced pluripotent stem cell culture medium provided by the invention, the risk of carrying animal-derived pathogene is effectively avoided, and the safety of the induced pluripotent stem cell in clinical application is improved. The culture medium provided by the invention can enable the induced pluripotent stem cells to proliferate quickly and has very high application values in clinical practice.

The invention discloses a method for enriching an influenza virus through utilizing an asialofetuin-containing magnetic bead. The method comprises the following steps of: (1) utilizing a vortex instrument to shock and disperse carboxylation magnetic microspheres; (2) using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and N-H-hydroxy succinimide (NHS) to activate the carboxyls of the carboxylation magnetic microspheres so as to obtain the magnetic microspheres with carboxyl activity; (3) directly adding the dissolved fetuin protein into the activated magnetic microspheres of step (2) for covalent binding; and (4) directly adding the magnetic microspheres bonded with the fetuin protein in the step (3) into a liquid to be detected so as to enrich the virus. According to the method, the built fetuin protein magnetic microspheres is directly added into the liquid to be detected so as to enrich the virus, and the detection can be carried out after the enrichment without intermediate links such as centrifugation, precipitation and the like, so that time is saved, and no special instruments are needed; and the method has the advantages of rapid sensitivity, strong antijamming capability, convenience, economy, simplicity, practicability, no environmental pollution and the like.

The invention provides a kit for diagnosis of early non-small cell lung cancer. A marker of the kit is protein of serum exosomes, and the exosome protein is exosome human fetuin A, namely AHSG or / andexosome extracellular matrix protein-1, namely ECM-1. The content of the marker in a sample is detected, and if the content of the marker in the sample is greater than the critical value range thereof, a tester can preliminarily judge that the sample has larger risk of non-small cell lung cancer. The marker in the kit is simple to extract, the preparation is convenient and rapid, the detection process is simple, and the kit has a good diagnostic effect on early non-small cell lung cancer.

The present invention discloses the use of fetuin and fetuin producing agents in methods and compositions for treating burn injuries in animals.

The present invention provides methods and pharmaceutical compositions of the human glycoprotein fetuin, or α2-HS glycoprotein, or fragments thereof to mitigate tissue damage associated with ischemia, particularly in stroke or in myocardial infarction.

The invention discloses a one-step type embryo culture liquid. The one-step type embryo culture liquid comprises substances of (+ / -)-alpha-lipoic acid, acetyl L-carnitine or acetyl L-carnitine hydrochloride and insulin, transferrin, selenium, Fetuin-A and platelet derived growth factor (PDGF) which play an important role in embryo culture and development. The one-step type embryo culture solutionprepared through the substances retain favorable components secreted into a culture solution in the embryo culture and development process, the effects of protecting and promoting the growth and development of cells and inhibiting decomposition and utilization of harmful products by the cells, and the problem is avoided that the blastocyst formation rate caused by mechanical damage likely to be brought to embryos and a stress reaction caused by changes of the culture environment in the transplanting process is low.

The present invention provides compositions and methods for selectively inhibiting the proliferation of stellate cells, which are important for the development of liver fibrosis upon liver injury. The invention describes conditioned media from immortalized hepatocytes as containing a death factor that induces apoptosis of activated liver stellate cells. This pro-apoptotic activity is shown to be associated with an 80 kDa protein, which is associated with a fetuin peptide sequence and an albumin peptide sequence.

The present invention provides compositions and methods for selectively inhibiting the proliferation of stellate cells, which are important for the development of liver fibrosis upon liver injury. The invention describes conditioned media from immortalized hepatocytes as containing a death factor that induces apoptosis of activated liver stellate cells. This pro-apoptotic activity is shown to be associated with an 80 kDa protein, which is associated with a fetuin peptide sequence and an albumin peptide sequence.

This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His Thr Phe Ser Gly Val Ala Ser Val Glu and correlates to amino acid no. 300-309 of fetuin, referred to herein as Fetuin Peptide Fragment (FPF 300-09). FPF 300-09 strongly induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the FPF 300-09 is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis. FPF 300-09 has a LD50 of 0.3-0.4 μM, while the LD50 for zinc-charged fetuin is 3-10 μM.

The present invention discloses composing components of an antheraea pernyi ovary cell culture medium, a preparation method of the antheraea pernyi ovary cell culture medium, and an application of the antheraea pernyi ovary cell culture medium in antheraea pernyi ovary cell culture. According to the present invention, a prepared amino acid and sugar mixing storage solution (MLM-AAS), an inorganicsalt storage solution (MLM-Salt), a vitamin storage solution (MLM-Vit), bovine serum albumin, fetuin and the like are prepared according to a certain ratio, and the pH value is adjusted to 6.2-6.4 toobtain a MLM-45 culture medium, wherein the prepared MLM-45 culture medium is added with fetal bovine serum and a penicillin and streptomycin mixing solution according to a certain volume ratio before the prepared MLM-45 culture medium is used, the volume ratio of the fetal bovine serum is 20%, and the volume ratio of the penicillin and streptomycin mixing solution is 1%. With a plurality of experiments, the following in vitro cell growth conditions are determined that: the culture temperature is 26-28 DEG C, the pH value is 6.2-6.4, and the osmotic pressure is 315-350 mOsm / kg. With the present invention, technical services are provided for researches in antheraea pernyi biology, antheraea pernyi pathogenic microorganism and related fields.

The invention relates to the technical field of separation culture of endothelial progenitor cells of umbilical blood, particularly a separation culture method for endothelial progenitor cells of umbilical blood and a kit of the method. The method comprises the following steps: carrying out adherent culture on a mononuclear cell of umbilical blood in advance; and carrying out cell culture on non-adherent cells, wherein a culture medium for cell culture is a full culture medium containing fetuin. Compared to cells obtained by conventional methods, the endothelial progenitor cells of umbilical blood cultured by the method provided by the invention are relatively uniform in shape, relatively high in convergence degree, relatively great in cell harvest yield, relatively fast in cell proliferation and relatively high in antigen presentation rate on cell surface.

The invention discloses nanometer fetuin test paper for monitoring diabetic retinopathy and a manufacturing process. The nanometer test paper comprises a fetuin antibody, and is used for detecting the content of fetuin in serum or other body fluids and monitoring the occurrence and development of diabetic retinopathy. The nanometer fetuin test paper comprises two nanometer electrode base layers, identification surface layers are adhered to the outer parts of the two nanometer electrode base layers, an adhesive layer is adhered to the outer part of one nanometer electrode base layer, and an anti-sticking layer is adhered to the outer part of the other nanometer electrode base layer. When the nanometer fetuin test paper is used, a worker places the prepared nanometer test paper on a conveying belt, the nanometer test paper is transmitted through the conveying belt, a second air cylinder is started to drive a second cutting knife to vertically cut the nanometer test paper on the conveying belt, and after vertical cutting is completed, the nanometer test paper continues to be transmitted through the conveying belt; and a first air cylinder is started to drive a first cutting knife to transversely cut the nanometer test paper, so that transverse cutting and vertical cutting of the nanometer test paper can be carried out at the same time, and the production efficiency of the nanometer test paper is improved.

The invention discloses a method for detecting the content of an SA alpha 2-3Gal sugar chain in a saliva sample by ELISA. According to the method, a fetal globulin is used as a standard substance, andthe content of the fetal globulin which has the same content as the SA alpha 2-3Gal sugar chain in the saliva sample under a certain saliva protein coating concentration can be calculated by utilizing a standard curve, so that the content of the SA alpha 2-3Gal sugar chain in the saliva sample can be calculated, and the quantitative result is accurate.

Pharmaceutical, dental and / or cosmetic composition consisting of purified Enamel Matrix Derivative (EMD) proteins which have a molecular weight between 1 and 55 kDa, formulated in a suitable pharmaceutical carrier. The composition is depleted of proteins which have a molecular weight between 56 and 160 kDa and an iso-electric point between 3-10. The purified Enamel Matrix Derivative (EMD) proteins are depleted of proteinase inhibitors, such as α1-antichymotrypsin and / or Fetuin A. The composition is preferably used for promoting and / or inducing regeneration of hard tissue, tissue mineralization, bone growth and / or bone regrowth, regeneration of dentin, cementogenesis, and / or binding between parts of living mineralized tissue, for bonding of a piece of living mineralized tissue to a bonding site on a piece of other living tissue, for endorsing binding between hard tissues, and / or for filling a mineralized wound cavity and / or tissue defect following from a procedure and / or trauma.

Fetuin-beads, a manufacturing method thereof and a method of concentrating and detecting influenza virus by the fetuin-beads are disclosed. The method of concentrating and detecting an influenza virus by the fetuin-beads comprises the steps of preparing fetuin-beads; mixing the fetuin-beads and a solution capable of providing salt ions to obtain a fetuin-bead solution; mixing the fetuin-bead solution and a sample comprising the influenza virus to concentrate the influenza virus onto the fetuin-beads to obtain a plurality of fetuin bead-influenza virus combinations; and collecting the fetuin bead-influenza virus combinations and using a virus testing method to detect the influenza virus on the fetuin bead-influenza virus combinations. Therefore, an easy and fast method to detect the influenza virus with timeliness and high accuracy is provided.

The invention concerns the identification of specific polypeptides, fragments variants thereof which can be used as markers for the efficacy of immunotherapy, particular for predicting responsiveness of a patient to immunotherapy.

The invention provides a serum-free mesenchymal stem cell nutrient solution, which is simple in formula, low in cost and high in safety. The serum-free mesenchymal stem cell nutrient solution comprises a serum-free animal cell culture medium, a B27 serum-free additive, bFGFs (basic fibroblast growth factors) and EGFs (epidermal growth factors), wherein the nutrient solution also comprises fetuin and antibiotics. The nutrient solution does not contain animal serum, has higher safety and definite formula components, and is suitable for clinical treatment. Meanwhile, according to the serum-free mesenchymal stem cell nutrient solution, human fat stem cells can be normally attached to the surface of a culture vessel and grow, the antibiotics are added into the formula components, and the formula is simpler compared with that of the general serum-free nutrient solution. For the fat stem cells cultured according to the conventional formula, the cells began to differentiate and slowly grow after two generations. Compared with the fat stem cells cultured according to the conventional formula, the fat stem cells cultured according to the formula of the serum-free mesenchymal stem cell nutrient solution do not have the phenomena of differentiation and slow growth after being tested, so that the serum-free mesenchymal stem cell nutrient solution is extremely suitable for the growth of the fat stem cells and gum stem cells.

Biomarkers are disclosed that facilitate the mechanisms associated with central nervous system disease worsening or activity, specifically multiple sclerosis. Methods are also disclosed for identification of biomarkers associated with disease worsening or activity in multiple sclerosis.

This invention characterizes the specific peptide fragment derived from specially prepared zinc charged fetuin and a method of preparation thereof, wherein the fragment was found to contain an apoptosis-inducing activity. Specifically, the amino acid sequence of this peptide is His Thr Phe Ser Gly Val Ala Ser Val Glu. The peptide induced apoptosis in LNCaP (prostate cancer) and HT-29 (colon cancer) cells without affecting CCD 18 Co (normal colon) cells. The in vitro tissue culture study demonstrated that the peptide is more potent than the parent molecule (full-length zinc charged fetuin) in inducing apoptosis. The peptide has a LD50 of 0.3-0.4 μM, while the LD50 for zinc-charged fetuin is 3-10 μM.

The present invention discloses a new pharmaceutic application of glucoprotein. In particular, it relates to application of fetuin fetua, AHSG in the preparation of medicine for curing cerebral ischemia injury including cerebral thrombosis, cerebral infarction and cerebral hemorrhage.